Benefits
Zero-calorie sugar replacement
Steviol glycosides are 200-300× sweeter than sucrose with negligible caloric contribution. Used in beverages, baked goods, dietary products. Heat-stable up to baking temperatures. Most commercial 'stevia' products are blends with erythritol, maltodextrin, or other bulking agents — pure stevia is impractical for cup-for-cup baking substitution.
Glycemic neutrality
In randomized studies, steviol glycosides produced no significant blood glucose or insulin response in people with and without diabetes. In one randomized study, stevioside at 250 mg three times daily changed neither blood glucose, blood pressure nor HbA1c compared with placebo, and the authors' stated conclusion was that steviol glycosides taken as a sweetener have no pharmacological effect (PMID 18397817). A 16-week safety study of rebaudioside A in people with type 2 diabetes likewise showed no significant change in HbA1c, fasting glucose or insulin versus placebo (PMID 18555575). The honest way to read this: stevia is useful because it lets you drop sugar out of a food or drink, not because it improves blood sugar control. It does not lower blood sugar and it does not treat diabetes.
Blood pressure: not shown at sweetener amounts
Blood pressure lowering has only been studied in people already diagnosed with high blood pressure, using pharmacological amounts of stevioside far above what anyone gets from sweetening food. It did not hold up: a randomized study of steviol glycosides at 250 mg three times daily found no significant change in blood pressure versus placebo in normotensive, hypotensive and diabetic participants (PMID 18397817), and a 16-week study in people with type 2 diabetes also showed no blood pressure change (PMID 18555575). Stevia is not a blood pressure treatment and should not be used as one. Do not change blood pressure medication because of stevia.
Gut microbiome: changed, with unclear meaning
A randomized human trial included stevia among 4 non-nutritive sweeteners tested in healthy adults. Stevia shifted the mix of gut bacteria but, unlike saccharin and sucralose in the same trial, it did not measurably worsen the body's handling of a glucose load over the two weeks tested. What these bacterial shifts mean for health over the longer term is not known. This trial is not among the references listed on this page.
WHO 2023 non-sugar sweeteners guideline
WHO 2023 conditional recommendation against using non-sugar sweeteners for weight control or NCD risk reduction includes stevia. Based on systematic review showing no long-term benefit for body weight/composition and possible association with type 2 diabetes and cardiovascular disease. In plain terms: stevia can take the place of sugar in what you eat and drink, but it is not a weight-loss aid and should not be used as one.
Dental and cariogenicity profile
The bacteria most linked to tooth decay cannot ferment steviol glycosides, so stevia does not feed them the way sugar does. Reports of mild antibacterial effects on mouth bacteria come from laboratory work, not from dental trials in people. None of the studies cited on this page tested stevia and dental health.
Forms and regulatory framework
FDA GRAS applies to high-purity steviol glycosides (mainly rebaudioside A and stevioside). Whole stevia leaf and crude leaf extract are not FDA-approved as sweeteners (only purified glycosides). Most commercial 'stevia' products are stevia leaf extract with bulking agents. Bitter aftertaste varies by glycoside profile — Reb A is sweeter and cleaner-tasting than stevioside.
Mechanism of action
Sweet taste receptor activation
Steviol glycosides bind the T1R2/T1R3 heterodimeric sweet taste receptor on tongue taste buds, generating a sweet sensation 200-400× more potent per molecule than sucrose. Different glycosides bind with slightly different kinetics — explaining the taste differences between stevioside (more licorice-like aftertaste), Reb A (cleaner but with detectable bitterness), and Reb M/Reb D (cleanest, most sucrose-like profile).
Non-absorption of intact glycosides
Steviol glycosides are not absorbed intact in the small intestine. They reach the colon where gut bacteria — primarily Bacteroides species — hydrolyze the glucose units to release steviol (the aglycone). Steviol is absorbed, conjugated to steviol glucuronide in the liver, and excreted predominantly in urine. This explains why steviol glycosides contribute no calories and don't raise blood glucose — the sweet molecule never reaches systemic circulation in its intact form.
Why steviol glycosides interact with the microbiome
Because gut bacteria are required to release steviol from the glycoside, steviol glycoside intake represents a substrate for specific microbial taxa. Repeated exposure can shift microbial composition toward those that metabolize the substrate. This is the mechanistic basis for the documented microbiome-altering effect - a real biological signal, with downstream glycemic significance still being characterized.
Proposed blood pressure mechanism (animal and lab studies only)
Stevioside has been shown in animal and isolated tissue studies to modulate vascular smooth muscle calcium channels and decrease vascular tone — the proposed mechanism for the modest blood pressure reduction observed at high doses. This is animal and isolated tissue work, not human evidence. In a randomized human study, steviol glycosides at 250 mg three times daily produced no significant change in blood pressure versus placebo (PMID 18397817), so this mechanism has not translated into a measurable effect in people, and certainly not at the amounts used to sweeten food.
Clinical trials
Multi-arm clinical trial in 120 healthy NSS-naive adults randomized to 2 weeks of saccharin, sucralose, aspartame, stevia, or control at sub-ADI doses.
Clinical population described in trial publication.
Multi-arm clinical trial in 120 healthy NSS-naive adults randomized to 2 weeks of saccharin, sucralose, aspartame, stevia, or control at sub-ADI doses. All four NSS distinctly altered stool and oral microbiome and plasma metabolome. Saccharin and sucralose impaired glycemic responses to oral glucose challenge; stevia and aspartame did not in this trial. Fecal microbiome transplant from human responders to germ-free mice transferred the glycemic phenotype — establishing causation. In short, stevia changed the mix of gut bacteria without any measurable effect on blood sugar handling over the two weeks tested. The mouse transplant part of this work is animal evidence and shows causation in mice, not in people. This trial is not among the four references listed on this page.
Two-year randomized double-blind placebo-controlled trial in 168 hypertensive Taiwanese adults randomized to stevioside 1500 mg/day or placebo.
Clinical population described in trial publication.
Two-year randomized double-blind placebo-controlled trial in 168 hypertensive Taiwanese adults randomized to stevioside 1500 mg/day or placebo. Blood pressure fell in the stevioside arm over the two years. Three limits matter. It was done in people already diagnosed with high blood pressure, so it says nothing about what stevia does for a healthy person. It used 1500 mg a day of stevioside, many times more than anyone gets from sweetening food and drink. And it was not replicated: a separate randomized study of steviol glycosides at 250 mg three times daily found no significant change in blood pressure versus placebo (PMID 18397817). This trial is also not among the four references listed on this page. Stevia used as a sweetener should not be expected to lower blood pressure, and it does not treat high blood pressure.
European Food Safety Authority FAF Panel evaluated proposed ADI modification from 4 to 6 or 16 mg/kg body weight/day steviol equivalents.
Clinical population described in trial publication.
European Food Safety Authority FAF Panel evaluated proposed ADI modification from 4 to 6 or 16 mg/kg body weight/day steviol equivalents. Confirmed that the existing acceptable daily intake of 4 mg per kg of body weight per day remains appropriate. This is a safety review of toxicology data, not a clinical trial, and it says nothing about health benefits. Currently authorized in the EU across 32 food categories. EFSA 2021 and 2022 opinions covered the safety of enzymatically-produced rebaudiosides M, D, and AM.
Conditionally recommended against using non-sugar sweeteners for weight control or to reduce risk of NCDs in adults or children.
Clinical population described in trial publication.
Conditionally recommended against using non-sugar sweeteners for weight control or to reduce risk of NCDs in adults or children. Based on evidence reviews finding limited long-term weight-loss benefit in clinical trials and possible associations with type 2 diabetes, cardiovascular disease, and all-cause mortality in observational studies. This applies to stevia along with every other non-sugar sweetener. Some researchers have argued the recommendation leaned too heavily on observational studies and gave too little weight to trials in which sweeteners replaced sugar, but as it stands the guideline advises against using stevia for weight control. Note also that this is a guideline, not a clinical trial, and that the observational associations it cites are associations, not demonstrated effects.